Literature DB >> 2650559

Injury induces increase of von Willebrand factor in rat endothelial cells.

M A Reidy1, M Chopek, S Chao, T McDonald, S M Schwartz.   

Abstract

This study examined the effects of injury on the content of von Willebrand factor (vWF) in rat aortic endothelium. Endothelial cells from normal, endotoxin-treated, and balloon-injured rats were stained with vWF antibodies and visualized using a biotinylated secondary antibody and avidin-tagged peroxidase. Endotoxin treatment and balloon injury caused a threefold increase in intracellular vWF, and immunoelectron microscopy showed the endoplasmic reticulum to stain heavily by the vWF antibody. Weibel-Palade bodies were not observed in all the cell profiles examined. The basement membrane of the endothelialized vessels showed no vWF staining; however, after endothelial denudation this matrix was clearly stained by the antibody. These results suggest that endothelial injury leads to an increased intracellular content of vWF that is localized primarily in the endoplasmic reticulum.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2650559      PMCID: PMC1879791     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  23 in total

1.  Increased factor VIII complex and defective ristocetin-induced platelet aggregation in liver disease.

Authors:  R Castillo; S Maragall; J Rodés; C Clemente; J Profitós; A Ordinas
Journal:  Thromb Res       Date:  1977-12       Impact factor: 3.944

2.  Cell replication in the aortic endothelium: a new method for study of the problem.

Authors:  S M Schwartz; E P Benditt
Journal:  Lab Invest       Date:  1973-06       Impact factor: 5.662

3.  Localization of factor-VIII-related antigen in human vascular subendothelium.

Authors:  J H Rand; I I Sussman; R E Gordon; S V Chu; V Solomon
Journal:  Blood       Date:  1980-05       Impact factor: 22.113

4.  Endothelial regeneration. III. Time course of intimal changes after small defined injury to rat aortic endothelium.

Authors:  M A Reidy; S M Schwartz
Journal:  Lab Invest       Date:  1981-04       Impact factor: 5.662

5.  An increased factor VIII antigen as an indicator of endothelial damage in measles.

Authors:  R Corda; M Alberti; L Caocci; G Putzolu; P M Mannucci
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

6.  Human von Willebrand factor: a multivalent protein composed of identical subunits.

Authors:  M W Chopek; J P Girma; K Fujikawa; E W Davie; K Titani
Journal:  Biochemistry       Date:  1986-06-03       Impact factor: 3.162

7.  Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure.

Authors:  R P Warrell; M B Hultin; B S Coller
Journal:  Am J Med       Date:  1979-02       Impact factor: 4.965

8.  Synthesis of antihemophilic factor antigen by cultured human endothelial cells.

Authors:  E A Jaffe; L W Hoyer; R L Nachman
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

9.  Synthesis of von Willebrand factor by cultured human endothelial cells.

Authors:  E A Jaffe; L W Hoyer; R L Nachman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

10.  Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon.

Authors:  M B Kahaleh; I Osborn; E C LeRoy
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

View more
  15 in total

1.  Differing microvasculature in the two major types of gastric carcinoma: a conventional, ultrastructural and ultrastructural immunolocalization study of von Willebrand factor.

Authors:  H Ohtani; H Nagura
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Inhibition of angiogenesis in vitro by Arg-Gly-Asp-containing synthetic peptide.

Authors:  R F Nicosia; E Bonanno
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

3.  Differential role of von Willebrand factor and P-selectin on microvascular thrombosis in endotoxemia.

Authors:  Kavita N Patel; Said H Soubra; Ricardo V Bellera; Jing-Fei Dong; Colleen A McMullen; Alan R Burns; Rolando E Rumbaut
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09-18       Impact factor: 8.311

4.  Von Willebrand factor in the outcome of temporal arteritis.

Authors:  M C Cid; J Monteagudo; J Oristrell; J Vilaseca; L Pallarés; R Cervera; C Font; J Font; M Ingelmo; A Urbano-Márquez
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

5.  Immune complex formation after xenotransplantation : evidence of type III as well as type II immune reactions provide clues to pathophysiology.

Authors:  Z E Holzknecht; S Coombes; B A Blocher; T B Plummer; M Bustos; C L Lau; R D Davis; J L Platt
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

6.  Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature.

Authors:  B Stoelcker; B Ruhland; T Hehlgans; H Bluethmann; T Luther; D N Männel
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

7.  Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries.

Authors:  V Lindner; R A Majack; M A Reidy
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

8.  Constitutive repression of interleukin-1alpha in endothelial cells.

Authors:  Gregory J Brunn; Soheyla Saadi; Jeffrey L Platt
Journal:  Circ Res       Date:  2008-02-21       Impact factor: 17.367

9.  Heterogeneous distribution of Weibel-Palade bodies and von Willebrand factor along the porcine vascular tree.

Authors:  J Gebrane-Younès; L Drouet; J P Caen; L Orcel
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

10.  Arteriolosclerosis of the human renal allograft: morphology, origin, life history and relationship to cyclosporine therapy.

Authors:  P Rossmann; J Jirka; M Chadimová; I Reneltová; F Saudek
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.